Licensing and R&D opportunities

Molecular diagnosis of T-ALL leukemia using the NUP-ABL fusion predicts therapeutic success
Molecular diagnosis using FISH or a PCR-based assay detecting the NUP214-ABL1 fusion can be used to predict the success of the tyrosine kinase inhibitor pathway
Plasmin therapy to enhance heamatopoetic stem cell mobilization; Plasmin inhibitors to inhibit Leukemogenesis
Plasmin agonists can be used to enhance HSC mobilization to treat leukopenia and neutropenia. Plasmin antagonists can be used to inhibit HSC mobilization to assist in treating malignant disorders such as leukemia, lymphoma and myeloma.
Aging markers in Serum - Physiological Age Markers
This biomarker can be used to scientifically prove the effect of cosmetics, food supplements, medicines, dietary compositions and other ingredients on both humans and animals.
A Novel Target to Inhibit Metastasis of Various Tumors
Metastasis is triggered because tumors have a lack of oxygen. Improving tumor blood supply by inhibiting the oxygen sensor Phd2 inhibits metastasis as shown for melanoma, pancreatic lung and carcinoma.
Combination therapy of alpha-galactosylceramide and TNF to combat cancer
The synergistic effect of combination therapy with a single dose of α-galactosylceramide and sub-therapeutic levels of TNF can be exploited to safely combat cancer without the typical side effects of TNF treatment.
SIP1, a target to prevent metastasis and a marker for breast cancer aggressiveness
Sip1 is a bio-marker for breast cancer stem cells, which are the cells responsible for tumor extension and metastasis. Sip1 can be used therapeutically to inactivate breast cancer stem cells aimed at lowering morbidity and mortality.
MALT-Paracaspase, a novel therapeutic target in oncology and inflammatory diseases
MALT1 paracaspase inhibition is a novel therapeutic modality in oncology and inflammatory diseases. Screening methods to identify inhibitory compounds are protected.
Diagnosis and Treatment of T-Cell Acute Lymphoblastic Leukemia using MYB
The duplication of MYB, a gene encoding for a transcription factor, can be used in the molecular phenotyping of T-ALL patients. Knock-down of MYB expression or inhibition of MYB can be exploited therapeutically.
Treatment and diagnosis of dementia
Detection of PRGN mutations or decreased PRGN mRNA or protein levels can be used as a diagnostic method for dementia or dementia risk. Increasing the levels of PRGN in patients at risk for dementia promises to be therapeutic.
Method for genetic diagnosis of familial Alzheimer's Disease and for generation of AD models
Detection of the described mutation in the promoter region of APP can be used in to diagnose familial Alzheimer´s disease. It also provides a method for the construction of transgenic cell lines or model organisms with increased APP production.
Novel, non-invasive biomarker for Alzheimer’s disease
Profiles of sugars derived from N-linked glycoproteins from blood serum can be used as biomarkers to diagnose or to monitor the progress of Alzheimer’s disease.
Treatment of Respiratory Distress Syndrome
VEGF treatment for Respiratory Distress Syndrome in neonates promises to be a curative treatment.
A novel target to treat obesity and diabetes
Blocking this glucose sensor target helps to reduce intestinal carbohydrate uptake and metabolism without having toxic side effects
Novel recombinant adenoviral vector
VIB scientists have developed novel recombinant high capacity adenoviral vectors that produce unprecedented, high levels of clotting factors.
Diagnosis, prognosis and theranosis of HIV related
This invention relates to the use of visfatin (mRNA or protein) level in blood samples to diagnose HIV infection, determine the evolution of the disease and to evaluate the efficacy of a treatment.

Get VIB business opportunity updates: